Javier Waksman MD, Dabt, Faact
About Javier Waksman MD, Dabt, Faact
Javier Waksman, MD, DABT, FAACT, serves as the Vice President and Head of Drug Safety at Sangamo Therapeutics, Inc. He has extensive experience in drug safety and pharmacovigilance, with previous roles at FibroGen, Pfizer, and Amgen.
Work at Sangamo Therapeutics
Javier Waksman serves as Vice President and Head of Drug Safety at Sangamo Therapeutics, Inc. since 2019. In this role, he oversees drug safety operations, ensuring the safety and efficacy of the company's therapeutic products. His responsibilities include strategic oversight of safety signal detection, management, and validation, as well as risk communication of validated signals. Waksman's expertise in assessing the safety of genomic therapies, including gene therapy and gene editing, is integral to his work at Sangamo.
Previous Experience in Drug Safety
Before joining Sangamo Therapeutics, Waksman held significant roles in drug safety at various organizations. He worked as Executive Director of Drug Safety and Pharmacovigilance at FibroGen, Inc. from 2018 to 2019. Prior to that, he was at Pfizer as Disease Area Cluster Lead for Safety Surveillance and Risk Management in Oncology from 2017 to 2018. Additionally, he served as Medical Director of Global Patient Safety at Amgen from 2011 to 2015, where he contributed to patient safety strategies.
Education and Expertise
Waksman earned his Bachelor of Science (BSc) in Biology/Biological Sciences from Ben-Gurion University of the Negev from 1983 to 1986. He later obtained his MD from the same university, completing his studies from 1986 to 1993. He also pursued a Fellowship in Medical Toxicology at the University of Colorado School of Medicine from 1999 to 2001. His educational background supports his expertise in drug safety, particularly in genomic therapies and medical toxicology.
Contributions to Medical Research
Javier Waksman has contributed to significant medical research, including participation in writing a publication on drug-induced liver injury (DILI). This publication, titled 'Drug-induced liver injury (DILI): Current status and future directions for drug development and the post-market setting,' addresses critical aspects of DILI in drug development. He is also a member of the CIOMS DILI working group, where he provides expertise in hepato-toxicology and drug-induced liver injury.
Clinical Experience
Waksman has clinical experience as an Internal Medicine Physician at University of Colorado Health from 2008 to 2011. He also served as Director of Medical Toxicology Practice at the same institution from 2009 to 2011. His clinical background enhances his understanding of drug safety and patient management in therapeutic settings.